Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma

doi:10.1007/s11912-015-0466-9

Review

. 2015 Sep;17(9):41.

doi: 10.1007/s11912-015-0466-9.

Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma

Amitkumar Mehta¹, Andres Forero-Torres

Affiliations

Affiliation

¹ Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, 1720 2nd Avenue South, NP2540, Birmingham, AL, 35294, USA, amitkumarmehta@uabmc.edu.

PMID: 26194424
DOI: 10.1007/s11912-015-0466-9

Review

Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma

Amitkumar Mehta et al. Curr Oncol Rep. 2015 Sep.

. 2015 Sep;17(9):41.

doi: 10.1007/s11912-015-0466-9.

Authors

Amitkumar Mehta¹, Andres Forero-Torres

Affiliation

¹ Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, 1720 2nd Avenue South, NP2540, Birmingham, AL, 35294, USA, amitkumarmehta@uabmc.edu.

PMID: 26194424
DOI: 10.1007/s11912-015-0466-9

Abstract

Rituximab, a monoclonal antibody (MAb) against CD20, was the first MAb approved by the US Food and Drug Administration (FDA) for treatment of B cell non-Hodgkin lymphoma (B-NHL). Conjugating toxins to MAb was a technical challenge; however, with improvements in linker technology, immunoconjugates were constructed and revolutionized cancer treatment. Gemtuzumab ozogamicin was the first antibody drug conjugate (ADC) approved by the FDA. Because of the success of brentuximab vedotin and ado-trastuzumab emtansine in treating Hodgkin lymphoma (HL) and HER2-positive breast cancer, respectively, newer ADCs are being investigated. Brentuximab vedotin is approved for both HL and anaplastic large cell lymphoma. Newer ADCs, such as polatuzumab vedotin (_targeting CD79b), pinatuzumab vedotin (_targeting CD22), inotuzumab ozogamicin (_targeting CD19), SAR3419 (_targeting CD19), IMGN529 (_targeting CD37), and SGN-CD19A (_targeting CD19), have shown promising preclinical and early clinical activity. These findings will change the landscape of B-NHL treatment away from age-old "CHOP"-based chemotherapies.

PubMed Disclaimer

Cited by

Development of Traceable Rituximab-Modified PEO-Polyester Micelles by Postinsertion of PEG-phospholipids for _targeting of B-cell Lymphoma.
Saqr A, Vakili MR, Huang YH, Lai R, Lavasanifar A. Saqr A, et al. ACS Omega. 2019 Nov 1;4(20):18867-18879. doi: 10.1021/acsomega.9b02910. eCollection 2019 Nov 12. ACS Omega. 2019. PMID: 31737848 Free PMC article.
The promising role of antibody drug conjugate in cancer therapy: Combining _targeting ability with cytotoxicity effectively.
Li WQ, Guo HF, Li LY, Zhang YF, Cui JW. Li WQ, et al. Cancer Med. 2021 Jul;10(14):4677-4696. doi: 10.1002/cam4.4052. Epub 2021 Jun 24. Cancer Med. 2021. PMID: 34165267 Free PMC article. Review.
From Life in the Sea to the Clinic: The Marine Drugs Approved and under Clinical Trial.
Cappello E, Nieri P. Cappello E, et al. Life (Basel). 2021 Dec 11;11(12):1390. doi: 10.3390/life11121390. Life (Basel). 2021. PMID: 34947921 Free PMC article. Review.
The Antitumor Activity of IMGN529, a CD37-_targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.
Hicks SW, Lai KC, Gavrilescu LC, Yi Y, Sikka S, Shah P, Kelly ME, Lee J, Lanieri L, Ponte JF, Sloss CM, Romanelli A. Hicks SW, et al. Neoplasia. 2017 Sep;19(9):661-671. doi: 10.1016/j.neo.2017.06.001. Epub 2017 Jul 25. Neoplasia. 2017. PMID: 28753442 Free PMC article.
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.
Hansen HP, Trad A, Dams M, Zigrino P, Moss M, Tator M, Schön G, Grenzi PC, Bachurski D, Aquino B, Dürkop H, Reiners KS, von Bergwelt-Baildon M, Hallek M, Grötzinger J, Engert A, Paes Leme AF, Pogge von Strandmann E. Hansen HP, et al. Onco_target. 2016 May 24;7(21):30523-35. doi: 10.18632/onco_target.8864. Onco_target. 2016. PMID: 27105521 Free PMC article.

See all "Cited by" articles

References

1. Blood. 2009 Sep 24;114(13):2721-9 - PubMed
1. Lancet Oncol. 2012 Apr;13(4):403-11 - PubMed
1. Cancer Treat Rep. 1986 Jan;70(1):3-7 - PubMed
1. Clin Cancer Res. 2009 Jun 15;15(12):4038-45 - PubMed
1. Leukemia. 2007 Nov;21(11):2240-5 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- The Lens - Patent Citations Database
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Blood. 2009 Sep 24;114(13):2721-9 - PubMed

[2] Blood. 2009 Sep 24;114(13):2721-9 - PubMed

[3] Lancet Oncol. 2012 Apr;13(4):403-11 - PubMed

[4] Lancet Oncol. 2012 Apr;13(4):403-11 - PubMed

[5] Cancer Treat Rep. 1986 Jan;70(1):3-7 - PubMed

[6] Cancer Treat Rep. 1986 Jan;70(1):3-7 - PubMed

[7] Clin Cancer Res. 2009 Jun 15;15(12):4038-45 - PubMed

[8] Clin Cancer Res. 2009 Jun 15;15(12):4038-45 - PubMed

[9] Leukemia. 2007 Nov;21(11):2240-5 - PubMed

[10] Leukemia. 2007 Nov;21(11):2240-5 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma

Affiliation

Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous